Trials / Completed
CompletedNCT03384329
Efficacy of Resveratrol in Depression
Efficacy and Safety of Resveratrol in the Treatment of Depression: Double-blind Randomized Placebo-controlled Parallel-group Study.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Russian Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times over the study period (before, in the middle, after the intervention, and in 2 week follow up).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Resveratrol Pill | Resveratrol 500 mg |
| DRUG | Placebos | Placebo Pills |
Timeline
- Start date
- 2018-07-04
- Primary completion
- 2019-08-27
- Completion
- 2019-09-18
- First posted
- 2017-12-27
- Last updated
- 2020-12-08
- Results posted
- 2020-11-17
Locations
1 site across 1 country: Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03384329. Inclusion in this directory is not an endorsement.